[Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
After six years of home haemodialysis and two years of continuous ambulatory peritoneal dialysis a 59-year-old woman developed an aluminium-induced osteopathy, myopathy and normochromic anaemia. She was at first treated with intravenous, then peritoneal, deferoxamine, 1 g every other day. Before treatment, 15.8 micrograms aluminium (Al) had been eliminated daily, with a peritoneal clearance of 0.3 ml/min; after intravenous deferoxamine a mean of 774.3 +/- 102.3 micrograms Al was eliminated per day, after peritoneal deferoxamine 646.7 +/- 89.6 micrograms of Al per day, with a peritoneal clearance of 2.2 +/- 0.9 (intravenous) and 1.9 +/- 0.7 ml/min (intraperitoneal). After four months of deferoxamine administration, mostly intraperitoneally as an out-patient, the osteomalacia clearly improved, as did the myopathy and anaemia.
Passlick
J
J
Abteilung für Nephrologie, Universität Düsseldorf.
Wilhelm
M
M
Busch
T
T
Grabensee
B
B
Ohnesorge
F K
FK
D000535:Aluminum / Q000097:blood / Q000506:poisoning*; D002908:Chronic Disease; D003676:Deferoxamine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D013997:Time Factors
D000535:Aluminum; D003676:Deferoxamine
Chronische Aluminium-Intoxikation bei kontinuierlicher ambulanter Peritonealdialyse. Therapie mit Deferoxamin.